← Back to Search

Cyclin-Dependent Kinase Inhibitor

Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer

Phase 3
Waitlist Available
Research Sponsored by EQRx International, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 27 months
Awards & highlights
Pivotal Trial

Summary

This trial is testing a combination of two drugs, lerociclib and letrozole, in postmenopausal women with advanced or recurrent low-grade endometrial cancer. The goal is to see if this combination is more effective than letrozole alone. Lerociclib helps stop cancer cells from growing, while letrozole lowers estrogen levels to slow cancer growth.

Eligible Conditions
  • Uterine Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 27 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 27 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Progression Free Survival (PFS)
Secondary study objectives
Overall Survival (OS)
Patient Reported Outcomes/Quality of Life
Progression Free Survival (PFS) by Investigator
+1 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Letrozole 2.5mg by mouth once a day (QD) + Lerociclib 150mg by mouth twice a day (BID)Experimental Treatment2 Interventions
Group II: Letrozole 2.5mg by mouth once a day (QD) + PlaceboPlacebo Group2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Letrozole 2.5mg
2019
Completed Phase 4
~1490

Find a Location

Who is running the clinical trial?

EQRx International, Inc.Lead Sponsor
3 Previous Clinical Trials
20 Total Patients Enrolled
GOG FoundationNETWORK
46 Previous Clinical Trials
17,650 Total Patients Enrolled
European Network of Gynaecological Oncological Trial Groups (ENGOT)OTHER
39 Previous Clinical Trials
18,206 Total Patients Enrolled

Media Library

Lerociclib (Cyclin-Dependent Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05712941 — Phase 3
Uterine Cancer Research Study Groups: Letrozole 2.5mg by mouth once a day (QD) + Lerociclib 150mg by mouth twice a day (BID), Letrozole 2.5mg by mouth once a day (QD) + Placebo
Uterine Cancer Clinical Trial 2023: Lerociclib Highlights & Side Effects. Trial Name: NCT05712941 — Phase 3
Lerociclib (Cyclin-Dependent Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05712941 — Phase 3
~0 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top